XJPX4570
Market cap27mUSD
Jan 09, Last price
468.00JPY
1D
-1.06%
1Q
10.12%
Jan 2017
-42.08%
IPO
-40.98%
Name
Immuno-Biological Laboratories Co Ltd
Chart & Performance
P/E
23.35
P/S
5.34
EPS
20.05
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
-3.83%
Revenues
817m
+2.78%
Net income
187m
P
CFO
134m
+405.61%
Dividend
Mar 27, 201350 JPY/sh
Profile
Immuno-Biological Laboratories Co., Ltd. engages in the research, development, manufacturing, and supply of various immunological research reagents worldwide. The company offers ELILSA, an assay kit to quantitatively measure targeted substances; and support research services on Alzheimer's disease, metabolic syndrome, and cancer, as well as customized services for production of customized antibodies and development of ELISA systems. It also provides LipoSEARCH, a customized services for profiling and analyzing of lipoprotein through gel-filtration high performance liquid chromatography method that can profile various clinical samples, such as tiny plasma or serum samples from both small animals and human beings for broad range of research fields including lipid metabolism, development of drugs for life-style related diseases, development of functional supplemental foods, and clinical studies. In addition, the company offers LipoTEST, a support tool for diagnostic and health checks at animal clinics; and customized biomarker testing services for Life-style related diseases. Further, it operates protein production business using transgenic silkworms for manufacturing of antibodies for research reagents and diagnostic products; human collagen for cosmetic materials; development of proteins for use in drugs; and other proteins production. The company was incorporated in 1982 and is headquartered in Fujioka, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | |
| Income | |||||
Revenues | 816,701 2.78% | 794,621 22.71% | 647,576 7.44% | ||
Cost of revenue | 436,814 | 456,310 | 464,225 | ||
Unusual Expense (Income) | |||||
NOPBT | 379,887 | 338,311 | 183,351 | ||
NOPBT Margin | 46.51% | 42.58% | 28.31% | ||
Operating Taxes | (62,050) | 9,119 | 8,625 | ||
Tax Rate | 2.70% | 4.70% | |||
NOPAT | 441,937 | 329,192 | 174,726 | ||
Net income | 186,694 -164.44% | (289,731) 11.97% | (258,767) -18.84% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | |||||
BB yield | |||||
| Debt | |||||
Debt current | 151,421 | 135,889 | 129,008 | ||
Long-term debt | 84,561 | 99,101 | 104,990 | ||
Deferred revenue | |||||
Other long-term liabilities | 10,886 | 4,615 | 3,917 | ||
Net debt | (593,212) | (528,174) | (729,352) | ||
| Cash flow | |||||
Cash from operating activities | 133,775 | 26,458 | (93,204) | ||
CAPEX | (16,000) | ||||
Cash from investing activities | (24,496) | 30,036 | (155,629) | ||
Cash from financing activities | 991 | 991 | 143,998 | ||
FCF | 432,975 | 417,344 | 66,180 | ||
| Balance | |||||
Cash | 734,136 | 614,164 | 508,350 | ||
Long term investments | 95,058 | 149,000 | 455,000 | ||
Excess cash | 788,359 | 723,433 | 930,971 | ||
Stockholders' equity | 226,894 | (980,815) | (691,083) | ||
Invested Capital | 1,285,285 | 2,273,162 | 2,273,314 | ||
ROIC | 24.84% | 14.48% | 7.93% | ||
ROCE | 25.12% | 26.18% | 11.59% | ||
| EV | |||||
Common stock shares outstanding | 9,313 | 9,313 | 9,313 | ||
Price | 530.00 30.22% | 407.00 24.46% | 327.00 -40.76% | ||
Market cap | 4,936,133 30.22% | 3,790,578 24.46% | 3,045,501 -40.76% | ||
EV | 4,342,921 | 3,264,404 | 2,317,149 | ||
EBITDA | 382,220 | 338,311 | 183,351 | ||
EV/EBITDA | 11.36 | 9.65 | 12.64 | ||
Interest | 1,130 | 1,073 | 641 | ||
Interest/NOPBT | 0.30% | 0.32% | 0.35% | ||